Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPD1 CD19 eCAR T cells in B-cell Lymphoma
NCT03208556Phase 1Unknown
- Sponsor
- Peking University
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iPD1 CD19 eCAR T cells in B cell lymphoma, sponsored by Peking University. Primary endpoint: Incidents of treatment related adverse events at 2 years. Status: unknown.
02
Drugs
iPD1 CD19 eCAR T cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03208556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208556.